Company
(Symbol)^#
(M)

Type Of
Financing

Number
Of
Shares,
Units
Or Warrants

Amount
Raised
(M)

Investors; Placement Agents; Details
(Date)^@

Accentia Bio-
pharmaceuticals
Inc. (ABPI)

Private placement of stock and warrants

1.647S and 0.824W

$8

The shares were sold at $5 each; the warrants are exercisable at $6.59 per share; Susquehanna Financial Group and Rodman & Renshaw LLC were placement agents (5/16)

Adherex
Technologies
Inc. (AMEX:ADH)

Private placement of stock and warrants

7.7S and 2.31W

$6.5

Units consisting of one share and 0.30 of a warrant were sold at $0.84 each; each whole, four-year warrant is exercisable at $0.97 per share (5/4)

Amazon
Biotech Inc.
(OTC BB:AMZB)

Private financing

ND

$0.25

Details on the financing were not disclosed; Amazon said it had commitments for another $0.35M in funding (5/31)

AspenBio Pharma Inc.
(OTC BB:APNB)

Private placement
of stock

0.55S

$0.76 $2.2M

The first part of a financing that totaled about closed in April; the shares were sold at $1.40 each (5/9)

Avigen Inc.
(AVGN)

Private placement of stock

3.94S

$21.2

Institutional investors purchased the stock at $5.37 per share; RBC Capital Markets was lead placement agent; CIBC World Markets was co-agent; investors included Biotechnology Value Fund, Apex Capital, Federated Kaufman Fund and Fort Mason Capital LP (5/11)

BioSyntech
Inc. (Canada;
CDNX:BSY)

Private placement of stock and warrants

7.125S and 3.56W

C$3 ($2.7)

The deal marked the third closing of a financing that totaled C$21; the five-year warrants are exercisable at C$0.65 per share; Desjardins Securities Inc. and Dundee Securities Corp. were placement agents (5/3)

ChemGenex
Pharmaceuticals
Ltd. (Australia;
CXSP)

Private placement of stock

34.88S

A$15 ($11.6)

Shares were sold at A$0.43 each in a deal lead by Merck Sante and including Charter Pacific Corp. Ltd.; up to A$0.5M more could be raised in a share purchase plan with existing investors (5/8)

ChondroGene
Ltd. (Canada;
CDNX:CDG)

Bought-deal financing

15.625S

C$25 ($22.5)

Westwind Partners Inc. was lead underwriter in the deal for a syndicate that included PowerOne Capital Ltd.; Canaccord Capital Corp.; Loewen, Ondaatje, McCutcheon Ltd.; and Paradigm Capital Inc. (5/12)

Cytomedix
Inc. (AMEX:GTF)

Warrants exercise

1.5S

$2.2

Holders of Class D warrants exercised them for 1.5M shares; in return, for each $7.50 spent, they got a new five-year Class D warrant exercisable at $3.50 per share (5/1)

Dyadic
International
Inc. (AMEX:DIL)

Warrants and options exercise

0.592S

$2.1

Most of the deal consisted of warrants exercised at $3.33 per share (5/3)

Emisphere
Technologies
Inc. (EMIS)

Private placement of stock

4S

$33

The shares were sold from a shelf registration at $8.26 each; ThinkEquity Partners LLC was lead placement agent; WR Hambrecht + Co. and WBB Securities LLC were co-agents (5/16)

4SC AG
(Germany;
FSE:VSC)

Private placement of stock

0.93S

€4.3 ($5.5)

The shares were placed with institutional investors at €4.65 each; Conrad Hinrich Donner Bank and M.M. Warburg were placement agents (5/11)

Gentium SpA
(Italy; GENT)

Private placement of stock and warrants

1.94S and 0.39W

$22.1

Gentium sold about 1.94M American depository shares at $11.39 per ADS; warrants to purchase about 0.39M ADSs are exercisable at $14.50 per ADS; ThinkEquity Partners LLC was lead placement agent; Rodman & Renshaw LLC and I-Bankers Securities Inc. were co-agents (5/31)

Hana
Biosciences
Inc. (HNAB)

Private placement of stock

4.7S

$40

The shares were sold at $8.50 each to institutional investors; Lehman Brothers Inc. was lead placement agent; Jefferies & Co. Inc. and Oppenheimer & Co. Inc. were co-placement agents (5/17)

Incitive Ltd.
(Australia;
ASX:ICV)

Public offering of stock

15S

A$3 ($2.3)

Incitive sold 15M shares at A$0.20 each in an initial public offering on the Australian Stock Exchange (5/3)

Isis
Pharmaceuticals
Inc. (ISIS)

Equity facility

N/A

N/A

Azimuth Opportunity Ltd. agreed to purchase up to $75M of Isis stock over 18 months, at times and in amounts decided by Isis (5/30)

Isotechnika
Inc. (Canada;
TSE:ISA)

Equity facility

N/A

N/A

Azimuth Opportunity Ltd. agreed to purchase up to C$40M ($36M) of Isotechnika stock over two years, at times and in amounts decided by Isotechnika (5/26)

Kane Biotech
Inc. (Canada;
CDNX:KNE)

Private placement of stock and warrants

2.18S and 1.09W

C$1.2 ($1.1)

Units consisting of one share and half a warrant were sold at C$0.55 each; each whole warrant is exercisable for 18 months at C$0.70 per share (5/10)

Medicure
Inc. (Canada;
AMEX:MCU)

Private placement of stock and warrants

16S and 4W

$25.6

The shares were sold at $1.60 each; the five-year warrants are exercisable at $2.10 per share; Deutsche Bank Securities Inc. was lead placement agent; co-agents were Needham & Co. LLC, GMP Securities LP and Versant Partners Inc. (5/5)

Medivation
Inc.
(AMEX:MDV)

Registered direct offering

3S

$14.25

The shares were sold from a shelf registration at $4.75 each; Emerging Growth Equities Ltd. was placement agent (5/16)

Migenix Inc.
(Canada; TSE:
MGI)

Sale of royalty interest

N/A

C$8.8 ($7.9)

Biotechnology Value Fund LP, along with Fort Mason Capital and Southpoint Capital Advisors, purchased a royalty interest in deals related to license agreements on the CPI-226 and MX-594AN products (5/4)

MultiCell
Technologies
Inc. (OTC BB:
MCET)

Stock purchase agreement

N/A

N/A

Fusion Capital Fund II LLC agreed to purchase up to $25M in MultiCell stock, at $1M per month over 25 months (5/4)

Nanogen
Inc. (NGEN)

Financing commitment

N/A

N/A

Azimuth Opportunity Ltd. agreed to purchase up to $25M of Nanogen stock over 18 months at a a small discount to market price (5/10)

Neurologix
Inc. (OTC BB:
NRGX)

Private placement of convertible stock and warrants

N/A and 2.22W

$12

The 9% Series C convertible stock was sold at $35 per share, with each convertible into 19.66 common shares; the seven-year warrants are exercisable at $2.05 per share; investors were the General Electric Pension Trust, the DaimlerChrysler Corp. Master Retirement Trust and funds managed by ProMed Management Inc. (5/11)

NicOx SA
(France;
Eurolist:NICOX)

Private placement of stock

4.552S

€45.5
($58.2)

Shares were sold at €10 each to institutional investors (5/3)

Osteologix
Inc.

Private placement of stock

ND

$10

The placement was made concurrent with a deal in which Osteologix gained a public listing through a reverse merger; investors included Nordic Biotech, previously the company's sole investor; Rodman & Renshaw and Roth Capital Partners were placement agents (5/24)

Peplin Ltd.
(Australia;
ASX:PEP)

Private placement of stock and rights issue

57.1S and 17.15W

A$40 ($30.2)

37.5M shares and 11.25M four-year options were placed with institutional investors; 19.6M shares and 5.9M options were sold in a rights issue; MPM Capital was lead institutional investor; Wilson HTM was placement agent; ABN Amro Morgans and Wilson HTM underwrote the rights issue (5/24)

Pheromone
Sciences
Corp. (Canada;
CDNX:PHS)

Private placement of stock and warrants

8.072S and 4.036W

C$3.2 ($2.9)

Units consisting of one share and half a warrant were sold at C$0.40 each; each full warrant is exercisable for 24 months at C$0.60 per share (5/25)

pSivida Ltd.
(Australia; PSDV)

Rights issue

48.25S

A$29 ($22.3)

Shareholders can purchase one new share for every eight held, at A$0.60 per share, an 18% discount to a 30-day average; Janney Montgomery Scott LLC is lead U.S.-based manager (5/2)

Raptor
Pharmaceutical
Inc.

Private placement of stock and warrants

8.33S and 8.33W

$5

The deal was made concurrent with Raptor's reverse merger with Highland Clan Creations Corp. (OTC BB:HCLN); shares were sold at $0.60 each, and the 18-month warrants are exercisable at $0.60 per share (5/26)

Tripos Inc.
(TRPS)

Sale of convertible stock and warrants

N/A and 0.55W

$5.4 (5/4)

The 10.5% stock is redeemable in two-years; the five-year warrants are exercisable at $3.50 per share; Midwood Capital purchased the securities; Seven Hills Partners LLC was placement agent

Vivus Inc.
(VVUS)

Registered direct offering

3.67S

$12

OrbiMed Advisors LLC led the financing, which also included an existing investor; the shares were sold at $3.27 each (5/10)

ZioPharm
Oncology Inc.
(OTC BB:ZIOP)

Private placement of stock and warrants

8S and 2.4W

$37

Shares were sold at $4.63 each, and the five-year warrants are exercisable at $5.56 per share; investors included ProQuest Investments LB I Group Inc., Emerging Technology Partners, Knott Partners, Panacea Asset Management LLC, Cycad Group, Henderson Global Investors and funds advised by Medical Strategy; Paramount BioCapital Inc. and Griffin Securities Inc. were co-placement agents (5/3)